| Dr Bina E Joseph, MD | |
|
320 Settlers Trace Blvd, Lafayette, LA 70508 | |
| (337) 981-9495 | |
| (337) 981-7451 |
| Full Name | Dr Bina E Joseph |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 36 Years |
| Location | 320 Settlers Trace Blvd, Lafayette, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346232212 | NPI | - | NPPES |
| 1666530 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KI0005X | Allergy & Immunology - Clinical & Laboratory Immunology | L11234R (Louisiana) | Secondary |
| 207K00000X | Allergy & Immunology | MD.11234R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lafayette General Medical Center | Lafayette, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy Asthma And Immunology Center Of Southwest Louisiana | 4880765502 | 2 |
News Archive
The Kentucky legislature unanimously passed landmark legislation to help seniors pay for long term care. The legislation enables seniors to pay for their long term care by selling their life insurance policies for as much as 10 times more than the cash surrender value and applying those proceeds toward their long term care.
The Medical Assistance Program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has helped more than 30,000 patients gain access to vital medications valued at more than $500 million, and a new program expansion will further increase access to vital cancer therapies for patients with the greatest financial need.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 1 days ago
| Entity Name | Allergy Asthma & Immunology Center Of Southwest Louisiana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437208840 PECOS PAC ID: 4880765502 Enrollment ID: O20080624000036 |
News Archive
The Kentucky legislature unanimously passed landmark legislation to help seniors pay for long term care. The legislation enables seniors to pay for their long term care by selling their life insurance policies for as much as 10 times more than the cash surrender value and applying those proceeds toward their long term care.
The Medical Assistance Program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has helped more than 30,000 patients gain access to vital medications valued at more than $500 million, and a new program expansion will further increase access to vital cancer therapies for patients with the greatest financial need.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bina E Joseph, MD 320 Settlers Trace Blvd, Lafayette, LA 70508 Ph: (337) 981-9495 | Dr Bina E Joseph, MD 320 Settlers Trace Blvd, Lafayette, LA 70508 Ph: (337) 981-9495 |
News Archive
The Kentucky legislature unanimously passed landmark legislation to help seniors pay for long term care. The legislation enables seniors to pay for their long term care by selling their life insurance policies for as much as 10 times more than the cash surrender value and applying those proceeds toward their long term care.
The Medical Assistance Program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has helped more than 30,000 patients gain access to vital medications valued at more than $500 million, and a new program expansion will further increase access to vital cancer therapies for patients with the greatest financial need.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 1 days ago
Dr. Erin Trahan Pratt, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 101 Rue Fontaine Bldg 2, Lafayette, LA 70508 Phone: 337-484-1414 Fax: 337-233-3188 | |
Dr. Alexandra Joseph Chastant, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 320 Settlers Trace Blvd, Lafayette, LA 70508 Phone: 337-981-9495 Fax: 337-981-7451 | |
Mr. Bernard C Fruge Jr., MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 320 Settlers Trace Blvd, Lafayette, LA 70508 Phone: 337-981-9495 Fax: 337-981-7451 | |
Dr. Wilton Lee Bergeron, M. D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 1505 Westgate Rd, Lafayette, LA 70506 Phone: 337-981-2588 | |
Dr. Elizabeth Bertucci Robertson, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 200 Petroleum Dr, Lafayette, Lafayette, LA 70508 Phone: 337-988-9999 Fax: 337-984-7003 | |
Elizabeth Renee Smith, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 101 Rue Fontaine Bldg 2, Lafayette, LA 70508 Phone: 337-484-1414 Fax: 337-233-3188 |